This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (29)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Alert me on articles by topic  Social Bookmarking   What's this?

Mamta Kalidas, MD; Hagop Kantarjian, MD; Moshe Talpaz, MD

JAMA. 2001;286:895-898.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Natural History

Chronic myelogenous leukemia (CML) is a disorder of hematopoietic stem cells¹ accounting for 15% of adult leukemias. The median age at presentation is between 50 and 60 years; 12% to 30% of patients at diagnosis are older than 60 years.

Chronic myelogenous leukemia classically progresses through 3 phases, becoming more resistant to treatment in each successive phase. The majority of patients present in the chronic phase, which may last 4 to 6 years and is often asymptomatic at diagnosis. In the accelerated phase, symptoms become worse and immature blasts increase in the peripheral blood. The duration of this phase may last as long as a year. The final and fatal blastic phase (>30% blasts in the bone marrow or peripheral blood) has features of an acute leukemia including fever, weight loss, bleeding, and anemia; this phase may last 3 to 6 . . . [Full Text of this Article]

Pathophysiology

Monitoring With Bcr-Abl

Evolution of Therapy in CML

Novel Therapies

New Agents

Conclusions

Author Affiliations: Departments of Bioimmunotherapy (Drs Kalidas and Talpaz) and Leukemia (Dr Kantarjian), M.D. Anderson Cancer Center, Houston, Tex.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression
Nakanishi et al.
Blood 2006;108:678-684.
ABSTRACT | FULL TEXT  

Interaction between the Interferon Signaling Pathway and the Human Glucocorticoid Receptor Gene 1A Promoter
Nunez et al.
Endocrinology 2005;146:1449-1457.
ABSTRACT | FULL TEXT  

IFN-{alpha} promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment
Gabriele et al.
Blood 2004;103:980-987.
ABSTRACT | FULL TEXT  

Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias
Jaiswal et al.
Proc. Natl. Acad. Sci. USA 2003;100:10002-10007.
ABSTRACT | FULL TEXT  

SKI-606, a 4-Anilino-3-quinolinecarbonitrile Dual Inhibitor of Src and Abl Kinases, Is a Potent Antiproliferative Agent against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K562 Xenografts in Nude Mice
Golas et al.
Cancer Res. 2003;63:375-381.
ABSTRACT | FULL TEXT  

Multifaceted Approach to the Treatment of Bcr-Abl-Positive Leukemias
O'Dwyer
The Oncologist 2002;7:30-38.
ABSTRACT | FULL TEXT